In Vivo Generated CAR T Cells to Reverse Fibrosis & Restore Cardiac Function

Time: 12:00 pm
day: Day One


• Generating transient, functional antifibrotic CAR T cells in vivo by delivering modified mRNA in T cell-targeted LNPs
• Observing efficient delivery and translation of modified mRNA encoding a CAR to T lymphocytes and a reduction in fibrosis
• Leveraging this technology as a therapeutic platform to treat various pathologies beyond cardiac disease